Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MRK

Merck & Co Inc

Dec 01 • 04:00PM ET

103.46

Dollar change +0.98
Percentage change 0.96	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	DJIA, S&P 500	P/E	57.47	EPS (ttm)	1.80	Insider Own	0.14%	Shs Outstand	2.54B	Perf Week	1.56%
Market Cap	262.17B	Forward P/E	12.17	EPS next Y	8.50	Insider Trans	-1.51%	Shs Float	2.53B	Perf Month	0.59%
Income	4.61B	PEG	5.72	EPS next Q	0.12	Inst Own	77.49%	Short Float / Ratio	0.71% / 2.52	Perf Quarter	-5.81%
Sales	58.14B	P/S	4.51	EPS this Y	-79.51%	Inst Trans	0.65%	Short Interest	18.02M	Perf Half Y	-8.05%
Book/sh	16.27	P/B	6.36	EPS next Y	454.84%	ROA	4.31%	Target Price	124.78	Perf Year	-6.05%
Cash/sh	3.48	P/C	29.75	EPS next 5Y	10.05%	ROE	10.75%	52W Range	99.14 - 119.65	Perf YTD	-6.75%
Dividend	2.70	P/FCF	19.91	EPS past 5Y	45.70%	ROI	6.13%	52W High	-13.53%	Beta	0.36
Dividend %	2.61%	Quick Ratio	1.12	Sales past 5Y	8.48%	Gross Margin	70.27%	52W Low	4.36%	ATR	1.67
Employees	69000	Current Ratio	1.38	Sales Q/Q	5.20%	Oper. Margin	13.83%	RSI (14)	54.64	Volatility	1.51% 1.55%
Optionable	Yes	Debt/Eq	0.85	EPS Q/Q	45.86%	Profit Margin	7.93%	Rel Volume	0.94	Prev Close	102.48
Shortable	Yes	LT Debt/Eq	0.82	Earnings	Oct 26 BMO	Payout	49.02%	Avg Volume	7.14M	Price	103.46
Recom	1.59	SMA20	1.13%	SMA50	0.35%	SMA200	-4.56%	Volume	6,722,007	Change	0.96%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115
Mar-06-23	Initiated	Jefferies	Buy	$125
Feb-22-23	Upgrade	Wolfe Research	Peer Perform → Outperform	$127
Jan-04-23	Upgrade	BofA Securities	Neutral → Buy	$110 → $130
Nov-18-22	Initiated	Credit Suisse	Outperform	$120
Oct-10-22	Upgrade	Guggenheim	Neutral → Buy
Sep-14-22	Upgrade	Berenberg	Hold → Buy	$95 → $100
Jul-06-22	Upgrade	Daiwa Securities	Neutral → Buy	$89 → $102
Jun-06-22	Resumed	SVB Leerink	Outperform	$102
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$80
Dec-17-21	Initiated	Goldman	Buy	$93
Dec-16-21	Initiated	Daiwa Securities	Neutral	$70
Dec-13-21	Downgrade	UBS	Buy → Neutral	$98 → $76
Dec-09-21	Initiated	Wells Fargo	Overweight	$90

Show Previous Ratings

Nov-30-23 05:00PM	FDA Grants Priority Review to Mercks Application for KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer (Business Wire)
Nov-29-23 10:58AM	12 Best Quality Stocks To Buy Now (Insider Monkey)
09:00AM	AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development (Business Wire)
08:26AM	Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study (Zacks)
Nov-28-23 01:17PM	Merck Announces First-Quarter 2024 Dividend (Business Wire)
06:45AM	Loading…
06:45AM	Mercks V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older (Business Wire)
Nov-25-23 04:22PM	11 Best Fortune 500 Dividend Stocks To Buy Now (Insider Monkey)
Nov-23-23 05:09PM	5 Best Income Stocks To Invest In (Insider Monkey)
Nov-22-23 12:15PM	20 Healthiest States in the US in 2023 (Insider Monkey)
Nov-21-23 07:20AM	UPDATE 1-Merck to acquire Caraway Therapeutics for up to $610 mln (Reuters)
07:20AM	Merck to buy private biotech Caraway in neuroscience deal (BioPharma Dive)
06:51AM	Merck to acquire Caraway Therapeutics for up to $610 mln (Reuters)
06:45AM	Merck to Acquire Caraway Therapeutics, Inc. (Business Wire)
Nov-20-23 06:51AM	5 Most Valuable Healthcare Companies in the World (Insider Monkey)
06:45AM	Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
09:43AM	Loading…
Nov-19-23 09:43AM	Ken Griffin Stock Portfolio: Top 10 Stock Picks (Insider Monkey)
Nov-17-23 11:29AM	Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer (Zacks)
Nov-16-23 05:40PM	FDA Approves Mercks KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (Business Wire)
Nov-15-23 07:15AM	Alkermes separates cancer drug business as new company Mural (BioPharma Dive)
Nov-14-23 05:25PM	Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023 (GlobeNewswire)
04:19PM	Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame. (The Wall Street Journal)
12:30PM	The S&P 500 Has Two Companies to Thank for the Slide in Earnings Estimates (The Wall Street Journal)
08:45AM	Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030 (PR Newswire)
Nov-13-23 07:12PM	The 3 Best Defensive Stocks for Uncertain Times (InvestorPlace)
07:05PM	13 Cheap Blue Chip Stocks To Buy (Insider Monkey)
04:03PM	Robert Bruce's Investment Strategy Leads to Notable Changes in Portfolio, Highlighting Merck ... (GuruFocus.com)
02:56PM	10 Healthcare Focused Hedge Funds and 10 Top Stock Picks (Insider Monkey)
Nov-10-23 07:40AM	Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer (Business Wire)
Nov-09-23 08:45AM	Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance (PR Newswire)
01:08AM	Deutsche warms to Merck; Ralph Lauren snags a buy rating: 4 big analyst picks (Investing.com)
06:45AM	Loading…
Nov-08-23 06:45AM	Merck to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-04-23 09:00AM	3 Trustworthy Blue-Chip Stocks to Buy Now (InvestorPlace)
Nov-03-23 09:46AM	The Zacks Analyst Blog Highlights Merck, Bank of America, AMD, Netflix and Union Pacific (Zacks)
Nov-02-23 04:37PM	Q3 Earnings Season Scorecard and Analyst Reports for Merck, Bank of America & AMD (Zacks)
Nov-01-23 06:50AM	Merck to Participate in the UBS BioPharma Conference (Business Wire)
06:45AM	FDA Approves Mercks KEYTRUDA (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer (Business Wire)
06:30AM	KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy (Business Wire)
Oct-30-23 04:35PM	13 Most Undervalued Pharma Stocks To Buy According To Analysts (Insider Monkey)
09:30AM	Can Diabetes, Weight-Loss Drugs Get Even Better (PR Newswire)
05:25AM	11 Best Immunotherapy Stocks To Buy Now (Insider Monkey)
Oct-28-23 03:26PM	Merck & Co., Inc. (NYSE:MRK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-27-23 10:01AM	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls (The Fly)
09:33AM	Company News for Oct 27, 2023 (Zacks)
Oct-26-23 03:25PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
08:08AM	12 Best Dow Jones Dividend Stocks According to Hedge Funds (Insider Monkey)
08:05AM	UPDATE 2-Merck quarterly profit tops expectations on COVID pill surprise (Reuters)
06:47AM	Merck: Q3 Earnings Snapshot (Associated Press Finance)
06:33AM	Merck quarterly profit tops expectations on COVID pill surprise (Reuters)
06:30AM	Merck Announces Third-Quarter 2023 Financial Results (Business Wire)
06:30AM	Merck 3rd-quarter profit tops expectations on COVID pill surprise (Reuters)
Oct-25-23 05:24PM	Amazon and Ford earnings, U.S. GDP: What to Watch (Yahoo Finance Video)
11:47AM	Amazon earnings, Merck reports, Southwest Airlines: 3 things to watch (Investing.com)
10:59AM	Is a Surprise Coming for Merck & Co. (MRK) This Earnings Season? (Zacks)
07:30AM	KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) (PR Newswire)
04:51AM	10 Most Effective Methods of Birth Control and Biggest Brands In This Space (Insider Monkey)
04:28AM	20 Countries with Lowest Rates of Cancer (Insider Monkey)
04:15AM	10 Best Dialysis and Kidney Disease Stocks to Buy (Insider Monkey)
Oct-24-23 11:02AM	12 Defensive Healthcare Dividend Stocks To Invest In (Insider Monkey)
08:00AM	Merck Senior Vice President Sarah Aiosa Named to Most Powerful Latinas List (ACCESSWIRE)
Oct-23-23 10:10AM	Charles River (CRL) Offers Access to Preclinical Cancer Research (Zacks)
09:50AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
03:39AM	Merck discontinues some cancer drug development with China's Sichuan Kelun (Reuters)
Oct-22-23 10:30AM	KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (Business Wire)
Oct-21-23 08:45AM	Mercks WELIREG (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) (Business Wire)
Oct-20-23 08:00PM	Stock Market Today: Stock Market News And Analysis (Investor's Business Daily)
04:30PM	AT&T, Merck-Daiichi Sankyo, Klaviyo: Top Stocks (Yahoo Finance Video)
01:02PM	Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs (Zacks)
10:00AM	Mercks KEYTRUDA (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer (Business Wire)
08:02AM	Mercks KEYTRUDA (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer (Business Wire)
08:01AM	KEYTRUDA (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (Business Wire)
08:00AM	KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
02:12AM	Morgan Stanley raised to Peerperform, Merck a Buy at UBS: 4 big analyst picks (Investing.com)
Oct-19-23 10:06PM	Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion (The Wall Street Journal)
07:30PM	Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs (Business Wire)
Oct-18-23 11:01AM	Merck (MRK) Gets CHMP Nod for Expanded Use of Antiviral Drug (Zacks)
Oct-17-23 07:23AM	UPDATE 1-EU regulator backs use of Merck's viral infection drug (Reuters)
07:00AM	EU regulator backs Merck's viral infection drug (Reuters)
06:45AM	Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease (Business Wire)
Oct-16-23 07:02PM	UPDATE 3-Merck's Keytruda gets FDA nod for expanded use in lung cancer (Reuters)
07:00PM	FDA Approves KEYTRUDA (pembrolizumab) for Treatment of Patients With Resectable (T4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery (Business Wire)
06:53PM	Merck's Keytruda gets U.S. FDA's nod for expanded use in lung cancer (Reuters)
10:47AM	CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer (Zacks)
06:45AM	European Commission Approves KEYTRUDA (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy (Business Wire)
Oct-15-23 12:00AM	Merck to open £1bn London research centre with plea for government support of industry (Financial Times)
Oct-13-23 07:45AM	Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS 1) (Business Wire)
Oct-12-23 05:50PM	(MRK) Rises As Market Takes a Dip: Key Facts (Zacks)
04:52PM	15 Worst Performing Dow Stocks YTD (Insider Monkey)
10:07AM	25 US Cities with Cleanest Air and Water (Insider Monkey)
Oct-11-23 10:15AM	Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit (Zacks)
06:35AM	AQR Capital Management: AUM, Performance, Stock Picks (Insider Monkey)
Oct-10-23 06:45AM	Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease (Business Wire)
06:30AM	Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
Oct-06-23 12:03PM	Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study (Zacks)
Oct-05-23 08:15AM	Merck is Collaborating to Address Antimicrobial Resistance (ACCESSWIRE)
07:00AM	Mercks KEYTRUDA (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery (Business Wire)
06:45AM	Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26 (Business Wire)
Oct-04-23 12:32PM	US plans shift of Merck COVID treatment to commercial market (Reuters)
Oct-03-23 10:08AM	The 10 pharma companies participating in Medicare price negotiations (Yahoo Finance Video)
10:00AM	Merck Helps To Improve Diversity in Clinical Trials Through Beacon of Hope (ACCESSWIRE)
Oct-02-23 12:49PM	Drugmakers sign on to negotiate Medicare prices under protest (Reuters)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Oosthuizen Johannes Jacobus	President, U.S. Market	Nov 09	Sale	102.38	2,081	213,061	18,191	Nov 13 07:36 AM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Nov 08	Sale	105.03	43,823	4,602,668	111,764	Nov 09 09:04 AM
Oosthuizen Johannes Jacobus	President, U.S. Market	Oct 30	Option Exercise	102.82	915	94,080	20,723	Oct 31 11:08 AM
MIZELL STEVEN	EVP, Chief HR Officer	Aug 14	Sale	109.01	4,250	463,292	22,935	Aug 15 04:08 PM
Guindo Chirfi	Chief Marketing Officer	Aug 03	Option Exercise	105.70	36,901	3,900,436	38,342	Aug 04 04:17 PM
MIZELL STEVEN	EVP, Chief HR Officer	Aug 03	Sale	105.49	4,500	474,701	27,185	Aug 04 04:06 PM
Romanelli Joseph	President, Human Health Int?l	Aug 02	Sale	107.37	59	6,335	0	Aug 03 04:08 PM
Romanelli Joseph	President, Human Health Int?l	Aug 02	Sale	107.37	30	3,221	20,569	Aug 03 04:08 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 04	Option Exercise	65.24	16,824	1,097,552	61,585	May 05 04:54 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 04	Option Exercise	118.22	907	107,226	20,207	May 05 05:09 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 04	Option Exercise	118.22	885	104,625	19,476	May 05 05:06 PM
LeCointe-Cephas Lisa	SVP Chief Ethics & Com Officer	May 04	Option Exercise	118.22	813	96,113	5,421	May 05 05:01 PM
Zachary Jennifer	EVP, General Counsel	May 04	Sale	117.59	19,141	2,250,834	35,128	May 05 05:13 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 04	Sale	117.53	15,875	1,865,843	45,710	May 05 04:54 PM
MIZELL STEVEN	EVP, Chief HR Officer	May 03	Option Exercise	75.55	52,000	3,928,540	73,085	May 05 05:19 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 03	Option Exercise	117.89	803	94,666	45,363	May 05 04:54 PM
LeCointe-Cephas Lisa	SVP Chief Ethics & Com Officer	May 03	Option Exercise	117.89	689	81,226	4,844	May 05 05:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	May 03	Sale	119.01	53,400	6,355,056	31,685	May 05 05:19 PM
Williams David Michael	EVP,Chief Info&Digital Officer	May 02	Option Exercise	56.04	6,035	338,201	18,568	May 03 04:29 PM
Williams David Michael	EVP,Chief Info&Digital Officer	May 02	Sale	116.82	7,509	877,222	11,059	May 03 04:29 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 01	Option Exercise	56.04	75,436	4,227,433	229,929	May 02 11:37 AM
Li Dean Y	Executive VP & President, MRL	May 01	Option Exercise	115.47	1,062	122,629	20,995	May 03 04:10 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 01	Option Exercise	115.47	930	107,387	44,879	May 03 04:24 PM
Litchfield Caroline	EVP & CFO	May 01	Option Exercise	115.47	866	99,997	32,118	May 03 04:07 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 01	Option Exercise	115.47	866	99,997	19,727	May 03 03:54 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 01	Option Exercise	115.47	866	99,997	18,901	May 03 03:00 PM
LeCointe-Cephas Lisa	SVP Chief Ethics & Com Officer	May 01	Option Exercise	115.47	643	74,247	4,376	May 03 03:11 PM
Williams David Michael	EVP,Chief Info&Digital Officer	May 01	Option Exercise	115.47	577	66,626	12,731	May 03 04:29 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 01	Sale	116.03	75,436	8,752,749	154,493	May 02 11:37 AM
Davis Robert M	Chairman, CEO & President	Apr 28	Option Exercise	56.04	143,329	8,032,157	415,146	Apr 28 05:15 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Apr 28	Option Exercise	62.07	66,163	4,106,737	220,656	May 02 11:37 AM
Davis Robert M	Chairman, CEO & President	Apr 28	Sale	114.93	143,329	16,472,845	271,817	Apr 28 05:15 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Apr 28	Sale	115.00	66,163	7,608,844	154,493	May 02 11:37 AM
Romanelli Joseph	President, Human Health Int?l	Apr 26	Buy	113.68	3	341	20,599	Jun 30 04:04 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Apr 13	Option Exercise	59.02	134,055	7,911,405	134,055	Apr 14 04:34 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Apr 13	Sale	115.07	134,055	15,425,068	0	Apr 14 04:34 PM
Romanelli Joseph	President, Human Health Int?l	Mar 24	Sale	104.65	35	3,663	20,596	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Mar 20	Buy	105.47	136	14,344	20,631	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Feb 21	Buy	109.20	11	1,201	20,495	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Feb 15	Sale	108.22	5,000	541,100	20,284	Feb 16 11:58 AM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 13	Sale	109.10	1,815	198,017	33,085	Feb 14 10:03 AM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 10	Option Exercise	106.72	1,205	128,598	12,505	Feb 13 04:17 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 09	Sale	107.00	5,000	535,006	34,900	Feb 10 11:28 AM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 06	Sale	104.25	4,436	462,473	39,900	Feb 08 10:27 AM
Zachary Jennifer	EVP, General Counsel	Feb 03	Option Exercise	56.04	75,436	4,227,433	129,356	Feb 06 04:21 PM
Zachary Jennifer	EVP, General Counsel	Feb 03	Sale	103.17	75,436	7,782,762	53,920	Feb 06 04:21 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Jan 09	Option Exercise	53.06	83,994	4,456,722	113,494	Jan 11 04:22 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Jan 09	Sale	112.29	83,994	9,431,915	29,500	Jan 11 04:22 PM
Romanelli Joseph	President, Human Health Int?l	Dec 19	Buy	109.04	7	763	20,484	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Dec 13	Buy	110.96	56	6,214	20,477	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Dec 06	Buy	109.39	30	3,282	20,421	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Dec 05	Buy	109.54	107	11,721	20,391	Jun 30 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience